JY 023
Alternative Names: JY023Latest Information Update: 28 Sep 2020
At a glance
- Originator Beijing Eastern Biotech
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Colorectal cancer; Lung cancer; Solid tumours
Most Recent Events
- 09 Sep 2020 Early research in Colorectal cancer in China (Parenteral) before September 2020 (Beijing Eastern Biotech, September 2020)
- 09 Sep 2020 Early research in Solid tumours in China (Parenteral) before September 2020 (Beijing Eastern Biotech, September 2020)
- 09 Sep 2020 Early research in Lung cancer in China (Parenteral) before September 2020 (Beijing Eastern Biotech, September 2020)